Microscopic N2 disease exhibits a better prognosis in resected non-small-cell lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 50, Issue 2, 2016, Pages 322-328

  Garelli, Elena ^a   Renaud, Stéphane ^a,b   Falcoz, Pierre Emmanuel ^a   Weingertner, Noëlle ^a   Olland, Anne ^a   Santelmo, Nicola ^a   Massard, Gilbert ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Lymph node ratio; Microscopic; N2; Non small cell lung cancer

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; CARCINOMA, NON-SMALL-CELL LUNG; EPIDEMIOLOGY; FRANCE; LUNG NEOPLASMS; LUNG RESECTION; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME FACTOR; TRENDS;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84992499985     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezw036     Document Type: Article

References (22)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Johnson DH, Rusch VW, Turrisi AT. Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:415-8.
3. Yamaguchi M, Sugio K. Current status of induction treatment for N2-stage III non-small cell lung cancer. Gen Thorac Cardiovasc Surg 2014;62:651-9.
4. Jonnalagadda S, Arcinega J, Smith C, Wisnivesky JP. Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer. Cancer 2011;117:4724-31.
5. Matsuguma H, Oki I, Nakahara R, Ohata N, Igarashi S, Mori K et al. Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes. Eur J Cardiothorac Surg 2012;41:19-24.
6. Nwogu CE, Groman A, Fahey D, Yendamuri S, Dexter E, Demmy TL et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg 2012;93:1614-9; discussion 1619-20.
7. Riquet M, Assouad J, Bagan P, Foucault C, Le Pimpec Barthes F, Dujon A et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg 2005;79:225-33.
8. Urban D, Bar J, Solomon B, Ball D. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer. J Thorac Oncol 2013;8:940-6.
9. Renaud S, Prim N, Antoni D, Schumacher C, Olland A, Santelmo N et al. A high lymph node ratio predicts loco-regional recurrence while microscopic N2 predicts survival after radiation therapy in pIIIA-N2 non-small cell lung cancer. J Radiat Oncol 2015;4:169-76.
10. Gobardhan PD, Elias SG, Madsen EV, van Wely B, van den Wildenberg F, Theunissen EB et al. Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study. Ann Surg Oncol 2011;18:1657-64.
11. Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008;26:1128-34.
12. Meacci E, Cesario A, Cusumano G, Lococo F, D'Angelillo R, Dall'armi V et al. Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt. Eur J Cardiothorac Surg 2011;40:656-63.
13. Thomas P, Dahan M, Riquet M, Massart G, Falcoz PE, Brouchet L et al. [Practical issues in the surgical treatment of non-small cell lung cancer. Recommendations from the French Society of Thoracic and Cardiovascular Surgery]. Rev Mal Respir 2008;25:1031-6.
14. Renaud S, Falcoz PE, Olland A, Reeb J, Santelmo N, Massard G. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio. Interact CardioVasc Thorac Surg 2015;20:222-7.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
16. Vansteenkiste JF, De Leyn PR, Deneffe GJ, Stalpaert G, Nackaerts KL, Lerut TE et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 1997;63:1441-50.
17. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:243S-65S.
18. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 2005;23:3257-69.
19. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70:1826-31.
20. Lorent N, De Leyn P, Lievens Y, Verbeken E, Nackaerts K, Dooms C et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004;15:1645-53.
21. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 2008;86:912-20; discussion 912-20.
22. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e314S-40S.